Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) has announced a conference call and webcast scheduled for July 7, 2025, at 8:00 a.m. ET to discuss Part A 16-week data from their Phase 2 APEX trial of APG777 in patients with moderate-to-severe atopic dermatitis.
The clinical-stage biotechnology company, which focuses on developing novel biologics for inflammatory and immunology conditions, will present results for APG777, their candidate targeting atopic dermatitis, asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The webcast will be accessible through the company's website, with a replay available after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – APGE
On the day this news was published, APGE declined 17.32%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Webcast to be held Monday, July 7th at 8:00 a.m. ET
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Webcast Details
Apogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When will Apogee Therapeutics (APGE) report Phase 2 APEX trial data for APG777?
How can investors access Apogee Therapeutics' Phase 2 APEX trial results webcast?
What conditions is Apogee Therapeutics' APG777 being developed to treat?
What type of data will be presented in Apogee's Phase 2 APEX trial results?
